Quoin Pharmaceuticals Ltd (QNRX) ADR EACH REPR 35 ORD SPON
Sell:$5.03Buy:$5.69
$0.52
(8.69%)
- This stock can be held in a
Stocks and Shares ISA
SIPP$0.52
(8.69%)$0.52
(8.69%)Company Information
About this company
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Key people
Key facts
- EPICQNRX
- LocationIsrael
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS74907L4095
- Market cap$3.53m
- Employees3
- Shares in issue20.59m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.